- |||||||||| BrevaRex (AR20.5) / Quest PharmaTech
Preclinical, Journal: Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment. (Pubmed Central) - Jun 25, 2022
Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY)...Histological studies of tumors obtained from treated mice demonstrated reduced cellularity, nuclear morphology compatible with apoptosis induction and active caspase-3 detection by immunohistochemistry. Overall, our results exemplify that these immunotoxins are potential drugs to treat Tn-expressing cancers.
- |||||||||| BrevaRex (AR20.5) / Quest PharmaTech
Journal: Novel Mutations in GPR68 and SLC24A4 Cause Hypomaturation Amelogenesis Imperfecta. (Pubmed Central) - Jan 26, 2022
Family 3 also had a homozygous missense mutation in SLC24A4 gene which was reported previously (c.437C>T, p.(Ala146Val)). This report not only expands the mutational spectrum of the AI-causing genes but also improves our understanding of normal and pathologic amelogenesis.
- |||||||||| BrevaRex (AR20.5) / Quest PharmaTech
Journal: Engineered high-affinity zinc binding site reveals gating configurations of a human proton channel. (Pubmed Central) - Sep 4, 2021
The lower affinity of Zn2+ in open channels is consistent with the idea that structural rearrangements within the transmembrane region bring Arg205 near position 116, electrostatically expelling Zn2+. This phenomenon provides direct evidence that Asp185 opposes position 116 in closed channels and that Arg205 moves between them when the channel opens.
- |||||||||| BrevaRex (anti-MUC1 monoclonal antibody) / Quest PharmaTech
Journal: Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe. (Pubmed Central) - Feb 13, 2021
In subsequent in vivo experiments in athymic nude mice bearing subcutaneous MUC1-expressing ovarian cancer xenografts, [Zr]Zr-DFO-AR20.5 clearly delineated tumor tissue, producing a tumoral activity concentration of 19.1 ± 6.4 percent injected dose per gram (%ID/g) at 120 h post-injection and a tumor-to-muscle activity concentration ratio of 42.4 ± 10.6 at the same time point. Additional PET imaging experiments in mice bearing orthotopic MUC1-expressing ovarian cancer xenografts likewise demonstrated that [Zr]Zr-DFO-AR20.5 enables the visualization of tumor tissue-including metastatic lesions-with promising tumor-to-background contrast.
- |||||||||| AR20 / Arbor Pharma, BrevaRex (anti-MUC1 monoclonal antibody) / Quest PharmaTech
Journal: Comparative ligand structural analytics illustrated on variably glycosylated MUC1 antigen-antibody binding. (Pubmed Central) - Nov 3, 2020
Although the bound conformation of peptide and glycopeptide is similar, the glycopeptide fluctuates less and resides in specific conformers for more extended periods. This structural analysis which gives a high-level view of the features in the system under observation, could be readily applied to other binding problems as part of a general strategy in drug design or mechanistic analysis.
- |||||||||| iniparib (BSI 201) / Sanofi
Enrollment change, PARP Biomarker, Metastases: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (clinicaltrials.gov) - May 22, 2012
P2, N=22, Completed,
This structural analysis which gives a high-level view of the features in the system under observation, could be readily applied to other binding problems as part of a general strategy in drug design or mechanistic analysis. N=45 --> 22
- |||||||||| iniparib (BSI 201) / Sanofi
Trial completion, PARP Biomarker, Metastases: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (clinicaltrials.gov) - May 22, 2012
P2, N=22, Completed,
N=45 --> 22 Active, not recruiting --> Completed
|
